Recent news on Adalimumab

New Analysis of Data Shows Treatment With Abbott's HUMIRA(R ...  -  May 22, 2007
PR Newswire (press release),DC showing patients with moderate to severely active Crohn's disease treated with HUMIRA(R) (adalimumab) maintenance therapy were almost 60 percent less

New Analysis of Data Shows Treatment With Abbott's HUMIRA(R ...  -  May 22, 2007
Earthtimes.orgCrohn's disease is a serious, chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than one million people in North America

Adalimumab May Induce Remission of Crohn's Disease  -  May 4, 2007
Medscape (subscription)May 4, 2007 — Adalimumab was effective in inducing remission of Crohn's disease in patients who could not tolerate infliximab treatment, according to the

Adalimumab shows potential for Crohn's disease  -  May 2, 2007
News-Medical.net,A study led by Mayo Clinic found that adalimumab (Humira) is an effective treatment for adults with Crohn's disease who do not respond to infliximab

Adalimumab is an effective treatment for refractory Crohn's disease  -  May 1, 2007
RxPG NEWS,By Mayo Clinic, [RxPG] A study led by Mayo Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn's disease who do not

Abbott Seeks US and EU Regulatory Approvals for HUMIRA(R ...  -  May 8, 2007
PipelineReview.com (press release),...(adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the US and juvenile idiopathic arthritis (JIA) in the European Union (EU).

Abbott's HUMIRA® (adalimumab) Receives Positive Opinion From ...  -  Apr 30, 2007
Medical News Today (press release),CLASSIC I (Clinical assessment of Adalimumab Safety and efficacy Studied as an Induction therapy in Crohn's disease) was a study of 299 patients with

Abbott's Humira (Adalimumab) Receives Positive Opinion from ...  -  Apr 27, 2007
PharmaLive.com (press release),Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA(R) (adalimumab) for the treatment of severe Crohn's disease.

Researchers identify new therapy for patients with Crohn's disease  -  May 1, 2007
EurekAlert (press release),A study led by Mayo Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn’s disease who do not respond to infliximab

Treatment of Crohn Disease with Anti-Tumor Necrosis Factor Agent  -  Apr 30, 2007
Annals of Internal MedicineThe full report is titled "Adalimumab Induction Therapy for Patients with Crohn Disease Previously Treated with Infliximab: A Randomized Trial.

Abbott's novel psoriasis biologic shows promise  -  May 10, 2007
In-PharmaTechnologist.com,While other drugs, such as Humira (adalimumab), bind to tumour necrosis factor-alpha, ABT-874, a fully human monoclonal antibody, has a novel mechanism

Australian biotechs Peptech and EvoGenix set to merge  -  May 9, 2007
Pharma Times (subscription),Johnson & Johnson in relation to their respective blockbuster antibody anti-tumour necrosis factor drugs Humira (adalimumab) and Remicade (infliximab).

'Mini-antibodies' in first-ever clinical trials  -  May 23, 2007
DrugResearcher.com,Disease and rheumatoid arthritis; Abbott's Humira (adalimumab) for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's.

Abbott: another promising year for Humira  -  May 9, 2007
Pharmaceutical Business ReviewHowever, in a small percentage of patients DMARDs prove to be too slow to work or entirely ineffective, in which case biologics such as Humira (adalimumab)

Abbott seeks US and EU approvals for Humira as a treatment for ...  -  May 9, 2007
News-Medical.net,HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the US and juvenile idiopathic arthritis (JIA) in the European Union (EU).

Abbott Labs seeks additional approval for Humira in children  -  May 9, 2007
Pharma Times (subscription),...to market Humira (adalimumab) as a treatment for juvenile rheumatoid arthritis (or juvenile idiopathic arthritis as it is referred to in Europe),

Peptech Acquiring EvoGenix In Cash, Stock Deal Worth A$156M  -  May 7, 2007
BioWorld Online,More royalty cash is paid by Abbott Park, Ill.-based Abbott Laboratories on Humira (adalimumab), also an anti-TNF blocker for RA.

Cimzia's setback paves way for other TNF inhibitors in Crohn's disease  -  Apr 30, 2007
Nature.com (subscription),At one point, Abbott's monoclonal antibody (mAb) drug Humira (adalimumab) was a year-and-a-half behind Cimzia. Now, having gained FDA approval in this

Abbott Reviews 2006 Accomplishments At Annual Shareholders’ Meeting  -  Apr 28, 2007
WebWire (press release),...and nutritional products businesses, highlighting key growth drivers such as its growing vascular business and flagship product, HUMIRA® (adalimumab).

Abbott Reviews 2006 Accomplishments at Annual Shareholders' Meeting  -  Apr 27, 2007
PR Newswire (press release),...and nutritional products businesses, highlighting key growth drivers such as its growing vascular business and flagship product, HUMIRA(R) (adalimumab).

Abbott's Humira for treatment of Crohn's disease  -  Apr 27, 2007
SpiritIndia,European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA® (adalimumab) for the treatment of severe Crohn's disease.

Abbott Seeks US and EU Regulatory Approval for HUMIRA(R ...  -  Apr 3, 2007
Drug Newswire (press release),...the European Medicines Agency (EMEA) seeking approval to market HUMIRA(R) (adalimumab) as a treatment for moderate to severe chronic plaque psoriasis.

Abbott Seeks US and EU Regulatory Approval for HUMIRA(R ...  -  Apr 2, 2007
Earthtimes.org...to the European Medicines Agency (EMEA) seekingapproval to market HUMIRA(R) (adalimumab) as a treatment for moderate tosevere chronic plaque psoriasis.

Market Report -- In Play (ABT)  -  Apr 2, 2007
MSN MoneyAbbott Labs seeks US and EU regulatory approval for HUMIRA (Adalimumab) in psoriasis Co announces it has simultaneously submitted a supplemental Biologics

Abbott Announces Opening Of New Biotechnology Manufacturing ...  -  Apr 10, 2007
Trading Markets,...manufacturing facility in Puerto Rico to support the long-term supply of its leading biologic agent, HUMIRA or adalimumab, and other future biologics.

Research and Markets: Eisai Has an Estimated Market Potential of ...  -  Apr 24, 2007
Business Wire (press release),Eisai is co-developing Abbott’s adalimumab (marketed as Humira) for markets in Japan, Thailand and Korea. Currently it is one of Abbott’s highest selling

Inflammation, Asthma, and Tumor Necrosis Factor-alpha  -  Apr 24, 2007
Medscape (subscription)The inhibitors include the monoclonal antibodies against TNF-alpha (infliximab and adalimumab) as well as the soluble TNF-alpha receptor fused to human

French Guidelines for Pretreatment Screening Inadequate to ...  -  Apr 10, 2007
DG NewsThe last specific TNFalpha inhibitor therapy that these cases had received were the chimeric antibody infliximab (19), the humanised antibody adalimumab

Abbott sees dip in Q1 earnings  -  Apr 19, 2007
Pharma Times (subscription),Pharmaceutical sales jumped 16.6% to $3.4 billion, with global sales of the rheumatoid arthritis drug Humira (adalimumab) reaching $571 million,

Abbott's new biotech plant on the 'Bio Island' good to go  -  Apr 12, 2007
BiopharmaReporter.com,The facility will now be the primary production site for Abbott's monoclonal antibody treatment, Humira (adalimumab), and large-scale manufacture of future

Abbott slashes the price of AIDS drug Kaletra and waits for ...  -  Apr 11, 2007
Pharma Times (subscription),...facility in Puerto Rico to support the long-term supply of its fully human monoclonal antibody Humira (adalimumab) and other future biologics.

Abbott Opens $450M Biotechnology Manufacturing Facility in Puerto Rico  -  Apr 10, 2007
Genetic Engineering News (press release),Abbott just opened a new biologics manufacturing facility in Puerto Rico to support the long-term supply of its leading biologic agent, Humira (adalimumab),

A wonder drug beat my teenage arthritis  -  Apr 10, 2007
Daily Mail,There are three different anti-TNF drugs on the market at present: Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab), delivered either by

In Brief  -  Apr 3, 2007
Nature.com (subscription),...is used in the manufacture of some of the most successful antibody drugs including Humira (adalimumab) from Abbott Labs of Abbott Park, Illinois,

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),Remicade (infliximab; Centocor, subsidiary of Johnson & Johnson of New Brunswick, New Jersey) and Humira (adalimumab; Abbott Laboratories, of Abbott Park,

New Drug Helps Ease Psoriasis  -  Feb 14, 2007
HealthCentral.com,13 (HealthDay News) -- Many patients with moderate to severe chronic psoriasis showed significant improvement after treatment with Humira (adalimumab),

Switching TNF-alpha blockers can be effective for rheumatoid ...  -  Feb 14, 2007
Therapeutics Daily (subscription) (press release),The analysis involved 6739 patients who started new anti-TNF treatment: 876 on adalimumab, 2826 on etanercept and 3037 on infliximab. During a mean of 15 .

New Drug Helps Ease Psoriasis  -  Feb 13, 2007
CBC News,The REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL) included 1200 patients.

New work programme for NICE announced  -  Feb 8, 2007
Media Newswire (press release),Adalimumab for moderate to severely active crohn's disease To appraise the clinical and cost-effectiveness of adalimumab for moderate to severely active

New work programme for NICE announced  -  Feb 7, 2007
netPR.pl (komunikaty prasowe),Single Technology Appraisals Adalimumab for moderate to severely active crohn's disease To appraise the clinical and cost-effectiveness of adalimumab

Psoriasis Patients Show Significant Improvement in Symptoms with ...  -  Feb 5, 2007
Drug Newswire (press release),REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL) evaluated both the short-term and

Psoriasis Patients Show Significant Improvement In Symptoms With ...  -  Feb 5, 2007
Medical News Today (press release),Psoriasis patients experienced a significant reduction in the signs of their disease when treated with Abbott's HUMIRA® (adalimumab), and they were

Psoriasis Patients Show Significant Improvement in Symptoms with ...  -  Feb 2, 2007
PR Newswire (press release),About the REVEAL Study REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL) evaluated both

New NICE guidance on its way  -  Feb 12, 2007
Healthcare Equipment and Supplies,It will also issue five rapid single technology (STA) appraisals on: Adalimumab for moderate to severely active Crohn's disease; Bevacizumab for non-small

New data shows Abbott Labs' Humira eases psoriasis  -  Feb 6, 2007
Pharma Times (subscription),The REVEAL study evaluated both the short-term and sustained clinical efficacy and safety of Humira (adalimumab) in 1200 patients with moderate-to-severe

Biologic Drug Humira Psoriasis Trial Provides Encouraging Results  -  Feb 2, 2007
Biologic Drug Report,Psoriasis patients experienced a significant improvement when treated with biologic drug Humira (adalimumab), according to results from a new Phase III

Reimbursement Curbs Seen Constraint on Use of Biologic Drugs for ...  -  Jan 30, 2007
Biologic Drug Report,With two TNF-alpha inhibitors, Humira (adalimumab) and Cimizia (certolizumab pegol), expected to be approved for treatment of Crohn's disease in 2007,

CAT licences out allergy drug to Canada's iCo Therapeutics  -  Jan 9, 2007
Pharma Times (subscription),...for hairy cell leukaemia, offer more promise. CAT already has the rheumatoid arthritis drug Humira (adalimumab), sold by Abbott Laboratories, on the market.

Injection battles childhood arthritis  -  Dec 12, 2006
Macleans,A recent study indicates the drug, called adalimumab (brand name Humira), is more effective than inactive placebo injections at improving the symptoms of

Current and Emerging Strategies in Biologic Therapy for IBD  -  Dec 4, 2006
Medscape (subscription)...[6] All patients received open-label induction with adalimumab 80 mg at week 0, and 40 mg at week 2. At week 4, patients (n = 778) were stratified according

Abbott's Humira gets US FDA approval for expanded indication  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),2006 DEC 17 - (NewsRx.com) -- Abbott announced that the US Food and Drug Administration (FDA) approved an expanded indication for Humira (adalimumab) that

The Impact Of Immunosuppressive Medications On Cardiovascular ...  -  Dec 1, 2006
Medical News Today (press release),...including the interleukin-1 receptor antagonist anakinra as well as the three TNFá blockers, adalimumab, etanercept, and infliximab.

Cytotoxic and Glucocorticoid Agents Increase CV Risk in Rheumatoid ...  -  Nov 29, 2006
Medscape (subscription)RA medications studied included methotrexate monotherapy (reference exposure), tumor necrosis factor–alpha antagonists (adalimumab, etanercept,

For RA Cardioprotection, Biologics Found Equal to Methotrexate  -  Nov 29, 2006
MedPage Today,Biologic agents Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab) and Kineret (anakinra) as a group carried the same risk as methotrexate

Crohn's Disease Is The Fourth Autoimmune Disease For Humira ...  Sep 10, 2006
...the US Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA® (adalimumab) as a ... -Medical News Today

DOH:Further Action Taken To Tackle Obesity As Minister Announces ...  Aug 31, 2006
Adalimumab (Humira, Abbott Laboratories Ltd) is a fully human recombinant monoclonal IgG1 antibody specific for tumour necrosis factor (TNF) alpha. ... -Medical News Today

(PRN) - Renaissance Hotels Rock With Fashion ... [+]  Sep 7, 2006
...[+]. (PRN) - Abbott Submits US and EU Regulatory Applications Seeking Approval for HUMIRA(R) (Adalimumab) as a Treatment for Crohn's Disease ... [+. ... -Bolsamania.com

Wyeth/Amgen's Enbrel to Achieve Blockbuster Status by 2010 for the ...  Sep 11, 2006
...it will continue to lead sales among biologics approved for psoriasis through 2015, despite competition from Abbott/Eisai's Humira (adalimumab) after its ... -PharmaLive.com

Rheumatoid Arthritis Drugs May Not Raise Cancer Risk  Aug 31, 2006
He was not involved in this study. TNF blockers include infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira). The ... -Forbes

Tumor Necrosis Factor Blockers May Not Cause Cancer After All  Aug 31, 2006
Administration to mandate adding a cancer risk warning to the labels of three TNF blockers: etanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira ... -eMaxHealth.com

Big Pharma holds drug and advocacy groups hostage  Sep 1, 2006
...letter of January 13, 2006, warning of “Hepatitis B Reactivation� associated with drugs like Enbrel (etanercept), Humira (adalimumab) and Remicade ... -Common Ground.ca

Clinical Trials Update: Aug. 29, 2006  Aug 29, 2006
Volunteers 18-75 who have moderate-to-severe active Crohn's, have stopped taking Remicade, and have not been treated with Humira (adalimumab) previously may ... -Forbes

NICE Welcomes Referral Of New Work Programme Topics, UK  Aug 31, 2006
...thromboembolism; varenicline for smoking cessation; alteplase for acute ischaemic stroke; drugs for refractory rheumatoid arthritis; adalimumab and leflunomide ... -Medical News Today

Developments With Established Biologic Agents  Sep 8, 2006
...was addressed by a poster at EULAR 2006 concerning clinical characteristics of RA patients over 6 years of open-label treatment and follow-up on adalimumab. ... -Medscape (subscription)

Biologics Define New Standard of Therapy in Psoriasis  Sep 7, 2006
Systemic anti-TNF biologics etanercept followed by infliximab, adalimumab and certolizumab pegol have raised the level of efficacy in an unprecedented manner ... -PharmaLive.com

Research and Markets: View Detailed P&L and Investment Review of ...  Sep 1, 2006
Oncology. Humira (D2E7; adalimumab) is a fully-human monoclonal antibody designed to specifically block the activity of TNF alpha. ... -Genetic Engineering News

Patients With More Severe Psoriatic Arthritis Benefit Most From ...  -  Nov 15, 2006
DG NewsWASHINGTON, DC -- November 15, 2006 -- The anti-tumor necrosis factor agent adalimumab should be used early in the diagnosis of psoriatic arthritis in

Adalimumab (Humira) Treatment Does Not Reduce Effect of Flu Shot ...  -  Nov 15, 2006
DG News..."This study evaluated the effects of adalimumab on antibody response to pneumococcal and influenza vaccines in adult RA patients."

Adalimumab Proves Effective For Children With Juvenile Rheumatoid ...  -  Nov 13, 2006
Medical News Today (press release),Adalimumab, an injectable anti-TNF therapy that has FDA approval for treating rheumatoid arthritis in adults, has proven effective in children with juvenile

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval for ...  -  Nov 14, 2006
Therapeutics Daily (subscription) (press release),...for HUMIRA(R) (adalimumab) that includes inhibiting structural joint damage and improving physical function in patients with psoriatic arthritis (PsA).

Abbott's HUMIRA® (adalimumab) Receives FDA Approval for Inhibiting ...  -  Nov 15, 2006
PipelineReview.com (press release),The expanded indication is based on results from an extension of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), the largest randomized,

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval for ...  -  Nov 14, 2006
PR Newswire (press release),Study Results The expanded indication is based on results from an extension of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT),

Current and Emerging Strategies in Biologic Therapy for IBD  -  Dec 4, 2006
Medscape (subscription)...[6] All patients received open-label induction with adalimumab 80 mg at week 0, and 40 mg at week 2. At week 4, patients (n = 778) were stratified according

Abbott's Humira gets US FDA approval for expanded indication  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),2006 DEC 17 - (NewsRx.com) -- Abbott announced that the US Food and Drug Administration (FDA) approved an expanded indication for Humira (adalimumab) that

ACR: Humira Does Not Affect Flu Vaccination Efficacy  -  Nov 16, 2006
MedPage Today,16 -- Vaccination against influenza or pneumococcal disease is safe and effective in patients with rheumatoid arthritis who are taking Humira (adalimumab),

New data confirms that Humira is the most complete anti-TNF ...  -  Nov 13, 2006
PharmaLive.com (press release),Each patient received either the biologic, adalimumab, or a placebo over a 30-day period. Those taking the biologic drug were given 80 mg on day 1 followed

Abbott's Humira granted US FDA priority review to treat ...  -  Nov 16, 2006
Therapeutics Daily (subscription) (press release),This Priority Review is based on findings released earlier this month from the GAIN study, Gauging Adalimumab Efficacy in Infliximab Non-Responders,

Humira Gets Expanded Approval for Psoriatic Arthritis  -  Nov 14, 2006
Forbes,14 (HealthDay News) -- The Abbott Laboratories (nyse: ABT - news - people ) drug Humira (adalimumab) has been given expanded approval by the US Food and

Abbott Labs Gets FDA OK For Added Humira Indication >ABT  -  Nov 14, 2006
Therapeutics Daily (subscription) (press release),Abbott Laboratories (ABT) has received the approval of the US Food and Drug Administration for an expanded indication for HUMIRA (adalimumab) that includes

Abbott's HUMIRA® Receives FDA Approval For Inhibiting Structural ...  -  Nov 23, 2006
Medical News Today (press release),Abbott announced today that the US Food and Drug Administration (FDA) approved an expanded indication for HUMIRA® (adalimumab) that includes inhibiting

ACR: Humira Shows 'Profound' Benefit for Kids With Rheumatoid ...  -  Nov 14, 2006
MedPage Today,Explain to parents who ask that this study suggests that Humira (adalimumab) - approved for adults with rheumatoid arthritis - is highly beneficial in

The Impact Of Immunosuppressive Medications On Cardiovascular ...  -  Dec 1, 2006
Medical News Today (press release),...including the interleukin-1 receptor antagonist anakinra as well as the three TNFá blockers, adalimumab, etanercept, and infliximab.

Cytotoxic and Glucocorticoid Agents Increase CV Risk in Rheumatoid ...  -  Nov 29, 2006
Medscape (subscription)RA medications studied included methotrexate monotherapy (reference exposure), tumor necrosis factor–alpha antagonists (adalimumab, etanercept,

For RA Cardioprotection, Biologics Found Equal to Methotrexate  -  Nov 29, 2006
MedPage Today,Biologic agents Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab) and Kineret (anakinra) as a group carried the same risk as methotrexate

Waiting list slashed  -  Nov 23, 2006
Bolton News,New wonder-drugs, etanercept and adalimumab, which produce a protein that reduces inflammation in the joints, are now available in the borough - but only 25

No Increase in Overall Cancer Rate Found Among Rheumatoid ...  -  Nov 16, 2006
DG NewsBiologics agents included in the study were adalimumab, etanercept and infliximab. Dr. Wolfe and colleagues studied data from a large US registry of RA

ACR: No Cancer Link Found with New Rheumatoid Arthritis Agents  -  Nov 15, 2006
MedPage Today,...seen in some clinical trials of the medications, added a warning on the labels of Remicade (inflixumab), Enbrel (etanercept), and Humira (adalimumab).

Study: Abbott's Humira effective for juvenile arthritis  -  Nov 13, 2006
MarketWatch..."Results demonstrated that participants receiving adalimumab had significantly fewer disease flares than those on placebo," the release said,

(PRN) - Mercator Reports Financial Results for Third Quarter, 2006 ...  -  Nov 14, 2006
Bolsamania.com,...(PRN) - Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients With

Rheumatoid arthritis drugs do not increase cancer risk  -  Nov 13, 2006
South Asian Women's Forum,Typically, however, biologics such as adalimumab, etanercept, infliximab, anakinra and abatacept, are used only as a second line therapy because of their

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional